Efficacy of initial caspofungin plus trimethoprim/sulfamethoxazole for ... - BMC Infectious Diseases

  • Maini R, Henderson KL, Sheridan EA, Lamagni T, Nichols G, Delpech V, et al. Increasing pneumocystis pneumonia, England, UK, 2000–2010. Emerg Infect Dis. 2013;19:386–92.

    Article  PubMed  PubMed Central  Google Scholar 

  • Bollee G, Sarfati C, Thiery G, Bergeron A, de Miranda S, Menotti J, et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest. 2007;132:1305–10.

    Article  PubMed  Google Scholar 

  • Hughes WT, Feldman S, Sanyal SK. Treatment of pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole. Can Med Assoc J. 1975;112:47.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lau WK, Young LS. Trimethoprim-sulfamethoxazole treatment of pneumocystis carinii pneumonia in adults. N Engl J Med. 1976;295:716.

    Article  CAS  PubMed  Google Scholar 

  • Winston DJ, Lau WK, Gale RP, Young LS. Trimethoprim-sulfamethoxazole for the treatment of pneumocystis carinii pneumonia. Ann Intern Med. 1980;92:62.

    Article  Google Scholar 

  • Hughes WT, Feldman S, Chaudhary SC, et al. Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of pneumocystis carinii pneumonia. J pediatr. 1978;92:285.

    Article  CAS  PubMed  Google Scholar 

  • Wazir JF, Ansari NA. Pneumocystis carinii infection. Update and review. Arch Pathol Lab Med. 2004;128:1023.

    Article  PubMed  Google Scholar 

  • Sun P, Tong Z. Efficacy of caspofungin, a 1,3-beta-D-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats. Med Mycol. 2014;52:798–803.

    Article  CAS  PubMed  Google Scholar 

  • Kamboj M, Weinstock D, Sepkowitz KA. Progression of Pneumocystis jiroveci Pneumonia in Patients receiving Echinocandin Therapy. Clin Infect Dis. 2006;43:e92–4.

    Article  CAS  PubMed  Google Scholar 

  • Bo Yu Yu, Yang L, Ye X, Xie J, Guo. Comparison of caspofungin and trimethoprim-sulfamethoxazole combination therapy with standard monotherapy in patients with pneumocystis jiroveci pneumonia following kidney transplantation: a retrospective analysis of 22 cases. Int J Clin Exp Med. 2017;10(1):1234–42.

    Google Scholar 

  • Choi TKimHyo-LimHongYu-MiLeeHeungsupSungSung-HanKimSang-Ho, et al. Is caspofungin really an effective treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review. Scand J Infect Dis. 2013;45(6):484–8.

    Article  PubMed  Google Scholar 

  • Cooley L, Dendle C, Wolf J, Teh BW, Chen SC, Boutlis C, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J. 2014;44(12b):1350–63.

    Article  CAS  PubMed  Google Scholar 

  • Miller RF, Noury JL, Corbett EL, Felton JM, De Cock KM. Pneumocystis carinii infection: current treatment and prevention. J Antimicrob Chemother. 1996;37(Suppl B):33–53.

    Article  CAS  PubMed  Google Scholar 

  • Jin F, Liu X-H, Chen W-C, Wang Zhang-LingFHuan-Ling. High initial (1, 3) Beta-d-Glucan concentration may be a predictor of satisfactory response of c aspofungin combined with TMP/SMZ for HIV-negative patients with moderate to severe pneumocystis jirovecii pneumonia. Int J Infect Dis. 2019;88:141–8.

    Article  CAS  PubMed  Google Scholar 

  • Tian Q, Si J, Jiang F, Xu R, Wei B, Huang B, Li Q, Jiang Z, Zhao T. Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection. HIV Med. 2021;22(4):307–13.

    Article  CAS  PubMed  Google Scholar 

  • Liu A, Sun R, Cao G, Liu X, Zhu H, Yang J. Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure. BMC Infect Dis. 2022;22(1):546.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature. 1988;334(6182):519–22.

    Article  CAS  PubMed  Google Scholar 

  • Po-Yi Chen,Chong-Jen Yu,Jung-Yien Chien,Po-Ren Hsueh. Anidulafungin as an alternative treatment for Pneumocystis jirovecii pneumonia in patients who cannot tolerate trimethoprim/sulfamethoxazole. Int J Antimicrob Agents. 2020;55(1):105820.

  • Maschmeyer G, Helweg-Larsen J, Pagano L, et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother. 2016;71:2405–13.

    Article  CAS  PubMed  Google Scholar 

  • Armstrong-James D, Stebbing J, John L, et al. A trial of caspofungin salvage treatment in PCP pneumonia. Thorax. 2011;66(6):537–8.

    Article  PubMed  Google Scholar 

  • Koshy R, Chen T. Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe Pneumocystis pneumonia. ID Cases. 2019;15:e00496.

    PubMed  PubMed Central  Google Scholar 

  • Lu YM, Lee YT, Chang HC, Yang HS, Chang CY, Huang CM, Wei J. Combination of echinocandins and trimethoprim/sulfamethoxazole for the treatment of Pneumocystis jiroveci pneumonia after heart transplantation. Transpl Proc. 2017;49:1893–8.

    Article  CAS  Google Scholar 

  • Powles MA, Liberator P, Anderson J, et al. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother. 1998;42:1985–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Desoubeaux G, Lemaignen A, Ehrmann S. Scientifc rationale for inhaled caspofungin to treat Pneumocystis pneumonia: a therapeutic innovation likely relevant to investigate in a near future. Int J Infect Dis. 2020;95:464–7.

    Article  CAS  PubMed  Google Scholar 

  • Luraschi A, Richard S, Hauser PM. Site-directed mutagenesis of the 1,3- beta -glucan synthase catalytic subunit of Pneumocystis jirovecii and susceptibility assays suggest its sensitivity to caspofungin. Antimicrob Agents Chemother. 2018;62:e01159–18.

    Article  PubMed  PubMed Central  Google Scholar 

  • Roux A, Canet E, Valade S, Gangneux-Robert F, Hamane S, Lafabrie A, et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis. 2014;20:1490–7.

    Article  PubMed  PubMed Central  Google Scholar 

  • Monnet X, Vidal-Petiot E, Osman D, Hamzaoui O, Durrbach A, Goujard C, et al. Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care. 2008;12:R28.

    Article  PubMed  PubMed Central  Google Scholar 

  • Limper AH, Offord KP, Smith TF, et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989;140:1204–9.

    Article  CAS  PubMed  Google Scholar 

  • Roux A, Gonzalez F, Roux M, et al. Update on pulmonary pneumocystis jirovecii infection in non-HIV patients. Médecine Et Maladies Infectieuses. 2014;44(5):185–98.

    Article  CAS  PubMed  Google Scholar 

  • Kim SJ, Lee J, Cho YJ, et al. Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection. J Infect. 2014;69:88–95.

    Article  PubMed  Google Scholar 

  • Bollée G, Sarfati C, Thiéry G, et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest. 2007;132:1305–10.

    Article  PubMed  Google Scholar 

  • Boonsarngsuk V, Sirilak S, Kiatboonsri S. Acute respiratory failure due to Pneumocystis pneumonia: outcome and prognostic factors. Int J Infect Dis. 2009;13:59–66.

    Article  PubMed  Google Scholar 

  • Damiani C, Le Gal S, Da Costa C, et al. Combined quantification of pulmonary pneumocystis jirovecii DNA and serum (1–3)-β-D-Glucan for Differential diagnosis of Pneumocystis Pneumonia and Pneumocystis colonization. J Clin Microbiol. 2013;51(10):3380–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Utili R, Durante-Mangoni E, Basilico C, Mattei A, Ragone E, Grossi P. Efficacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe pneumocystis pneumonia in solid organ transplant recipients. Transplantation. 2007;84:685–8.

    Article  CAS  PubMed  Google Scholar 

  • Song JC, Stevens DA. Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes. Crit Rev Microbiol. 2015;42(5):1–34.

    Google Scholar 

    • Adblock test (Why?)

    Comments

    Post a Comment

    Popular posts from this blog

    Rashes that look like scabies: Causes, symptoms, and treatment - Medical News Today

    Image
    Scabies is a skin condition that occurs as the result of a mite known as Sarcoptes scabiei. The rash that results from scabies may appear similar to other skin conditions, such as psoriasis, eczema, or contact dermatitis. In this article, we look at what a scabies rash looks like. We also look at other rashes that are similar in appearance and their treatment options. Scabies is a common condition that occurs as the result of an infestation of a microscopic skin mite called Sarcoptes scabiei. The mites burrow under the skin, causing intense itching and a rash. The Centers for Disease Control and Prevention (CDC) describes the rash as pimple-like. On darker skin, the rash may be more difficult to see, but a person should be able to feel it. According to DermNet, a scabies rash is varied in appearance, and may appear as: pimple-like on the limbs and trunk widespread or coin-shaped small blisters scales lesions in the armpits, groin, navel, areolas, scrotum, buttocks, and along the penil
    Read more

    Urinary Tract Infection (UTI): Causes, Symptoms & Treatment - Cleveland Clinic

    Image
    Can I prevent a urinary tract infection? The following lifestyle changes can help prevent urinary tract infections: Practice good hygiene Practicing good hygiene is one of the best ways to help prevent UTIs. This is especially important if you have a vagina because your urethra is much shorter, and it's easier for E. coli to move from your rectum back into your body. Always wipe from front to back after a bowel movement (pooping) to avoid this. During your menstrual cycle, it's also a good idea to regularly change your period products, including pads and tampons. You should also avoid using any deodorants on your vagina. Drink plenty of fluids Drinking extra fluids — especially water — each day can help flush out bacteria from your urinary tract. Healthcare providers recommend drinking six to eight glasses of water daily. Change your peeing habits Peeing can play a big role in getting rid of bacteria from your body. Your pee is a waste product, and each time you empty your bla
    Read more

    Symtuza: Uses, side effects, alternatives, and more - Medical News Today

    Image
    The Food and Drug Administration (FDA) approves prescription drugs such as Symtuza to treat certain conditions. Symtuza is FDA-approved to treat HIV-1 in adults and children who weigh at least 40 kilograms (kg), which is about 88 pounds (lb). It's approved for people who: have just been diagnosed with HIV and haven't started treatment yet, OR are changing from another HIV treatment and: have been on a stable antiretroviral regimen for at least 6 months (this means you haven't had any changes to your HIV drugs for at least 6 months) have a viral load (the amount of HIV in your blood) that's less than 50 copies per milliliter (mL) have HIV that doesn't have mutations (changes) that could make it resistant (less likely to respond) to darunavir or tenofovir (two of the active drugs in Symtuza) HIV explained HIV stands for human immunodeficiency virus. There are two forms of this virus, HIV-1 and HIV-2. HIV-1 is the most common form. HIV is transmitted through body fluid
    Read more